Background: Graft-versus-host disease (GVHD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT). Transplacental maternal engraftment (TME), the presence of maternal T cells in peripheral blood before transplantation, is detectable in a significant proportion of patients with severe combined immunodeficiency (SCID). Although the presence of TME is associated with a decreased risk of rejecting a maternal graft, it is unknown whether TME plays a role in development of GVHD after HSCT. Objective: The purpose of this study was to determine whether the presence of pretransplantation TME is associated with posttransplantation GVHD in patients with SCID. Methods: This was an institutional retrospective review of 74 patients with SCID undergoing transplantation between 1988 and 2014. The incidence of acute graft-versus-host disease (aGVHD) was compared in patients with versus those without TME. Confounding variables, such as donor type and conditioning regimen, were included in a multivariate regression model. Results: TME was identified in 35 of 74 children. Post-HSCT aGVHD developed with an incidence of 57.1% versus 17.9% in those without TME (P < .001). In univariate analysis donor type (mother) and GVHD prophylaxis (T-cell depletion) were also significant predictors of aGVHD. In multivariate analysis TME and chemotherapy conditioning were independent risk factors
Severe combined immunodeficiency (SCID) is a genetically heterogeneous group of immune disorders characterized by a reduced number of T lymphocytes associated with a functional or quantitative defect in B lymphocytes, natural killer (NK) cells, or both. [1] [2] [3] A recent analysis from 11 states in the United States participating in newborn screening for SCID estimates the incidence at 1 in 58,000 live births. 4 SCID results in susceptibility to a variety of infections; if untreated, it is typically fatal within the first years of life. Although enzyme replacement and gene therapy might be of benefit to some patients with SCID, the current mainstay of treatment is hematopoietic stem cell transplantation (HSCT), which offers curative immune reconstitution. 5 The ideal donor for HSCT is an HLA-matched sibling; however, for 75% to 80% of patients, an HLA-matched sibling will not be available. In these cases HSCT from an unrelated donor is usually considered. However, for many patients (especially those with rare HLA genotypes), finding a matched unrelated donor is not possible. For others, the delay imposed by the process of finding and collecting cells from an unrelated donor can lead to an increased risk of morbidity and mortality related to infection. 6, 7 Therefore HSCT with a haploidentical related donor can provide substantial benefit for patients who do not have a matched related or unrelated donor source or who have active infection and need HSCT urgently. 6 In choosing a parent for stem cell donation under these circumstances, one factor to consider is the presence or absence of transplacental maternal engraftment (TME).
The human placenta allows for bidirectional passage of nucleated cells between mother and fetus 8, 9 ; in healthy infants the immune system eradicates these cells. In contrast, patients with SCID might lack the functional immunity required to reject circulating maternal T cells, resulting in persistent TME in up to 40% of these patients. [10] [11] [12] [13] Although TME can be asymptomatic, some infants with SCID and TME can have clinical symptoms of graft-versus-host disease (GVHD) before HSCT. 10, 13 GVHD in patients with SCID can manifest as cutaneous involvement characterized by localized or diffuse rashes ranging from fine maculopapular or morbilliform erythema to general erythroderma and alopecia. Liver involvement can also be observed (hepatosplenomegaly with increased liver enzyme levels, histologic signs of cell-mediated inflammation, and cholestasis). 10 Gastrointestinal tract involvement primarily manifests as diarrhea; hematologic manifestations, such as eosinophilia, thrombocytopenia, and even hemophagocytosis, can also be observed. 14, 15 Because the presence of TME can indicate a degree of host tolerance for maternal antigens, as well as a potential source of rejection of nonmaternal cells, 16, 17 maternal haploidentical transplants are generally preferred over paternal donors if TME is detected.
Parental mismatched grafts, which are typically a readily available stem cell source for patients without an HLA-matched donor, are used regularly, with excellent outcomes in patients with SCID. 7, 18 However, GVHD is a common side effect of HSCT; approximately 20% of patients with SCID receiving haploidentical HSCT have acute graft-versus-host disease (aGVHD), whereas 10% have severe (grade III/IV) aGVHD. 6 Chronic graft-versus-host disease (cGVHD) is observed in approximately 23% of CD34-selected haploidentical HSCTs for SCID. 6 Risk factors for the development of GVHD are primarily related to donor factors, such as HLA disparity, but host factors can play a role. 19, 20 Given the association of pre-existing TME with pre-HSCT GVHD, we hypothesized that the risk of post-HSCT GVHD might be higher in TME 1 patients with SCID compared with TME 2 patients with SCID. Here we report on the presence of TME and its effects on the development of aGVHD and cGVHD in patients with SCID undergoing transplantations between 1988 and 2014 at the University of California, San Francisco.
METHODS Patients
Eligible patients included those with a diagnosis of SCID who underwent first HSCT from 1988-2014 at the University of California, San Francisco, Benioff Children's Hospital. Diagnoses were made based on genetic testing when available or clinical criteria, as previously published. 21 Two patients with Omenn syndrome were not included because of the uncertain mechanism of immune hyperactivity in this setting, as well as difficulty in distinguishing posttransplantation aGVHD from pretransplantation autoimmunity. A total of 88 records were reviewed; patients were further excluded based on unavailability of TME testing results (n 5 13) or insufficient follow-up available for diagnosis of aGVHD (n 5 1). Leaky SCID was not considered an exclusionary criterion. 
Detection of maternal engraftment

Transplantation procedure
Stem cell products were T-cell depleted ex vivo by using a variety of methods if donor HLA allele typing differed from that of the recipient at 2 or more loci or, in the case of 1 patient, at the DRB1 locus only. Soybean agglutination/sheep red blood cell E-rosetting was used before 1996 (n 5 7 23 Bone marrow from matched or single allele-mismatched donors was unmanipulated, except for RBC or plasma depletion, depending on ABO mismatch. Patients undergoing matched or single-mismatched HSCT typically received GVHD prophylaxis with cyclosporine with or without methotrexate or mycophenolate mofetil. Patients were defined as requiring a second transplant if additional conditioning and stem cell infusion was required after the initial transplant. Stem cell boost refers to patients requiring an additional stem cell infusion without conditioning. aGVHD and cGVHD were diagnosed clinically based on established criteria. 24 Histopathologic examination was typically used to confirm or refute the presence of GVHD, when possible.
Statistical analysis
Statistics were performed with NCSS v8.0 (NCSS, Kaysville, Utah) and GraphPad Prism v6.05 (GraphPad Software, La Jolla, Calif) software. Categorical comparisons were made with the Student t test or, in contingency analysis with low frequencies, the Fisher exact test; P values were determined by using a 2-tailed model. Overall survival was estimated by using the method of Kaplan and Meier and compared with the log-rank test. Multivariate analysis was performed by using logistic regression.
RESULTS
Patients' characteristics
Of 90 patients eligible for analysis, 74 had records of maternal engraftment testing available. Of these, the following genetic etiologies were found: Artemis deficiency (n 5 19), IL-2 receptor common g chain (IL-2Rcg) deficiency (n 5 17), recombination-activating gene (RAG) 1/2 deficiency (n 5 13), IL-7 receptor a (IL-7Ra) deficiency (n 5 7), adenosine deaminase deficiency (n 5 2), and 1 patient each with CD3d deficiency, DNA protein kinase catalytic subunit deficiency, cartilage hair hypoplasia, and reticular dysgenesis (Table I) . For 12 patients, the genetic cause was unknown.
Transplant characteristics
Patients underwent transplantation at a median of 139 days of life (range, 13 days to 25.6 months old). Conditioning regimens varied and are described in Table II . Donors included siblings (n 5 15), mothers (n 5 44), fathers (n 5 7), or unrelated donors J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 2 (n 5 8). GVHD prophylaxis was with ex vivo TCD (with or without additional agents) in a majority of cases (n 5 50). Other patients received a calcineurin inhibitor with (n 5 18) or without (n 5 6) methotrexate. TME 1 patients were more likely to be treated with a maternal stem cell source (82.9% vs 38.5%, P 5 .001) with ex vivo TCD (85.7% vs 51.3%, P 5 .02). TME 1 patients received unconditioned transplants in 62.9% of cases compared with 38.5% of TME 2 patients (P 5 .103).
TME
Pretransplantation TME was identified in 35 (47.3%) of 74 patients and varied significantly based on SCID subtype (P 5 .016). TME was more commonly identified in patients with IL-7Ra SCID (6/6 [100%]) and IL-2 receptor common g chain SCID (11/17 [64.7%]). TME was identified in 3 (23.1%) of 13 patients with RAG1/2 SCID and 8 (42.1%) of 19 patients with Artemis SCID. TME was detected in 23 (44.2%) of 52 patients with NK 1 SCID compared with 12 (54.5%) of 22 patients with NK 2 SCID (P 5 .45); TME was not detected in the patient with reticular dysgenesis. There was no difference in the rate of TME in the more recent STR era (19/ 
GVHD
Pretransplantation GVHD was present in 8 patients. TME was detected in all of these patients at levels ranging from 1% to 87% in patients for whom STR analysis was performed. These patients were included in this analysis, but a separate analysis was performed excluding patients with pretransplantation aGVHD, and results were similar (see Tables E1-E8 in this article's Online Repository at www.jacionline.org for subset). Posttransplantation aGVHD of any grade developed in 36.5% of patients (95% CI, 25.5% to 47.5%). Grade II to IV aGVHD was diagnosed in 28.4% (95% CI, 18.1% to 39.7%) of all patients, and grade III to IV aGVHD was diagnosed in 9.5% (95% CI, 2.8% to 16.1%) of all patients. Of the 72 evaluable patients who survived more than 100 days after transplantation, cGVHD was diagnosed in 6 (8.3%; 95% CI, 1.9% to 14.7%) patients; 3 (4.2%; 95% CI, 0% to 8.8%) of these patients had extensive cGVHD.
TME and risk for post-HSCT aGVHD
In the 39 patients without TME, 7 (17.9%) had grade I to IV aGVHD compared with 20 (57.1%) of the 35 patients with TME (relative risk [RR], 3.2; P 5 .0006; Fig 1) . The incidence of grade II to IV aGVHD was 15.4% in the 39 TME 2 patients compared with 42.9% in the 35 TME 1 patients (RR, 2.8; P 5 .011). The risk of grade III to IVaGVHD was also 2.8-fold higher in patients with TME, although this did not reach statistical significance (P 5 .24, Table III) .
Univariate analysis was performed, examining the following potential confounding factors that might also influence the development of aGVHD: recipient sex, age at transplantation, conditioning regimen, donor type, donor ID, GVHD prophylaxis, and SCID type. Of these, donor type (mother) was associated with a higher risk of aGVHD (RR, 3.0; P 5 .05), and GVHD prophylaxis with calcineurin inhibitor plus methotrexate was associated with a lower risk of aGVHD (RR, 0.25; P 5 .04), although this was used primarily in the closely matched setting. Because of the small number of patients in this study, multivariate analysis was possible only for the presence of TME, conditioning type, and donor type (Table IV) . TME remained a strong and significant independent predictor of aGVHD (RR, 2.75; P 5 .006) in multivariate analysis, as did the use of cytotoxic conditioning without serotherapy (RR, 1.42; P 5 .02). Compared with maternal donors, use of a paternal donor was associated with a statistically significantly higher risk of aGVHD (RR, Tables E1-E8 ). Among patients receiving maternal donor transplants, TME 1 patients remained at a significantly higher risk for aGVHD (RR, 3.8; 95% CI, 1.2-9.3; P 5 .0097) compared with TME 2 patients, with no TME 2 recipient having grade III to IV aGVHD. This was also true for the subset of patients receiving TCD transplants (RR, 2.7; 95% CI, 1.2-5.9; P 5 .009). The method of TCD had no statistically significant effect on the development of aGVHD of any grade, although this analysis is confounded by the increased rate of serotherapy use in grafts depleted by using negative selection methodology compared with those using depletion by means of CD34 1 selection. For patients receiving cytotoxic conditioning, the RR for aGVHD was also increased in TME 1 patients (RR, 3.8; 95% CI, 1.2-12; P 5 .026).
For the 31 patients receiving serotherapy (alemtuzumab or antithymocyte globulin) during their conditioning regimen, the rate of GVHD was quite low compared with those who did not receive serotherapy (n 5 43, see Tables E9 and E10 in this article's Online Repository at ww.jacionline.org). Grade II to IV aGVHD occurred in 12.9% of patients receiving serotherapy versus 39.5% of those not receiving it (RR, 0.33; 95% CI, 0.12-0.88; P 5 .03).
Lastly, in the subset of patients in whom TME was analyzed using STR analysis (n 5 38), TME was detected in 19 (50.0%). Similar to the entire cohort, rates of grade I to IV and II to IV aGVHD were higher in TME 1 patients (73.7% vs 15.8% and 47.4% vs 10.5%; P 5 .0008 and P 5 .03, respectively). Interestingly, the 5 patients with IL-7Ra SCID in this subset were all TME 1 , and none had aGVHD of any grade, whereas the other 14 patients in whom TME was detected using STR all had aGVHD (including 3 patients who also had pretransplantation GVHD). Conversely, in the 19 patients in whom no TME was detected using STR analysis, only 3 (15.8%) had aGVHD (RR, 6.3; 95% CI, 2.2-18; P < .0001). No patient with TME of less than 10% had grade III or IV aGVHD, whereas 4 of 13 patients with TME of 10% or greater had grade III or IV aGVHD. Of note, the only patients with TME of greater than 10% who did not have GVHD of any grade were the patients with IL-7Ra-deficient SCID.
TME and risk for post-HSCT cGVHD
Of the 37 TME 2 patients surviving more than 100 days, 2 (5%) had cGVHD (1 limited and 1 extensive). Of the 35 TME 1 patients who survived more than 100 days, 4 (11%) had cGVHD (2 limited and 2 extensive; RR, 2.1; P 5 .42). Subset analysis showed no statistically significant increase in risk of cGVHD for TME 1 patients in any subset.
Overall survival and event-free survival
Overall survival for the entire cohort was 80% (95% CI, 70.5% to 86.3%; Fig 2) , with a median follow-up of 7 years (range, 2 months to 25 years); the presence or absence of TME was not associated with overall survival (P 5 .45).
In the entire cohort 15 patients required a second transplantation, 7 of whom died. An additional 3 patients died after unconditioned stem cell boost or donor lymphocyte infusion. Six patients died without receiving any posttransplantation cell infusions. Thirty-eight patients survived without the need for any posttransplantation cell infusions; an additional 12 survived after receiving an unconditioned stem cell boost or donor lymphocyte infusion.
Long-term event-free survival, which was defined as survival without the need for a second (conditioned) transplant, was 67.6% (Fig 3) . In the TME 1 group 10 of 35 required a second transplant or died compared with 14 of 39 in the TME 2 group (RR, 0.80; 95% CI, 0.4 to 1.5; P 5 .67). In the subset of patients with TME receiving a maternal transplant (n 5 29), 13 required a posttransplantation cell infusion. Among the TME 2 patients receiving maternal transplants, 9 of 15 required a posttransplantation cell infusion (RR, 1.34; 95% CI, 0.7-2.4; P 5 .53).
DISCUSSION
These results demonstrate a higher rate of aGVHD in patients with SCID with pretransplantation TME. This association was confirmed in multivariate analysis controlling for conditioning regimen and donor identity, as well as subset analyses evaluating smaller and more homogenous populations. The incidence of TME in this SCID cohort was 47.3%; this is similar to rates (range, 40% to 52%) observed in other studies. 3, 6, 10 In the Primary Immune Deficiency Treatment Consortium (PIDTC) cohort reported by Pai et al, 6 grade II to IV aGVHD was observed in 21% of mismatched related transplants; grade III to IV aGVHD was observed in 10%, and cGVHD was observed in 16%. Similarly, in our cohort 5 (17%) of 44 maternal transplant recipients had grade III to IV aGVHD, and this was strongly *Two patients in the TME 2 group were not evaluable for cGVHD.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 2 predicted by the presence or absence of TME (all were TME 1 ). No TME 2 maternal transplant recipient had grade III to IV aGVHD, despite the fact that TME 1 patients received a lower T-cell dose. Although the biologic reasons for this are not well understood, one possible hypothesis is that TME 1 patients have active subclinical GVHD, which is then exacerbated after infusion of any T cells with the donor graft.
Interestingly, TME was observed in all 7 NK 1 patients with IL-7Ra SCID, and despite the presence of TME in all of the IL-7Ra patients, none of them had aGVHD. This suggests that although IL-7Ra might be dispensable for the development of phenotypically normal CD16/CD56
1 NK cells, they might differ functionally from NK cells found in patients with other types of NK 1 SCID, such as RAG1/2 and Artemis SCID, in whom TME was less common. The mechanism for this is unknown but implies a specific lack of function causing a reduced capacity for cellular rejection in IL-7Ra-deficient NK cells.
Another unexpected finding was the association of paternal donors with the development of posttransplantation GVHD independent of the presence of TME. Studies in adult transplantations have demonstrated an increased risk of GVHD associated with female versus male donors (possibly mediated by Y-antigens in male recipients) 25 ; however, little is known regarding maternal-fetal tolerance in the perinatal period. Tolerance to noninherited maternal antigens has been attributed to better survival using maternal donors, regardless of the recipient's sex. 26 This tolerance might impart a resistance to aGVHD in patients with maternal donors compared with those with paternal donors. Another proposed mechanism is a so-called graft-versus-graft effect of infused paternal cells inciting an inflammatory reaction against HLA-mismatched but previously tolerant maternally engrafted cells. This phenomenon is difficult to evaluate in this cohort because only 1 TME 1 patient underwent transplantation using a paternal donor (the patient had grade 2 aGVHD). TME detection methodology differences do not seem to explain this because all paternal-donor GVHD developed in patients with TME tested by using STR analysis.
In the most recent multi-institutional retrospective analysis of patients with SCID undergoing transplantation, only 37% of recipients had been tested for the presence or absence of TME 6 ; it was examined in 62% of the first 50 patients enrolled in the more recent prospective PIDTC protocol. 3 Given the higher risk of aGVHD observed in TME 1 patients with SCID, an effort should be made to identify TME in the pretransplantation period, when possible, especially when considering a maternal or paternal donor. When conditions allow, approaches for enhanced GVHD prophylaxis should be considered in these patients. Use of serotherapy-based conditioning in this cohort partially abrogated the risk of GVHD caused by the presence of TME. Although serotherapy (antithymocyte globulin or alemtuzumab) is often administered in patients considered to be at high risk of rejection, this paradoxically can exclude TME 1 patients who might also benefit from serotherapy (at an appropriately reduced dose for recipients of T cell-depleted grafts) because of the reduction in aGVHD risk associated with its use.
Other options include the use of posttransplantation GVHD prophylaxis in situations in which historically none has been used (TCD haploidentical transplants). Sirolimus is a potentially attractive option in this setting in that it has been shown to preferentially spare regulatory T cells, thus possibly allowing for immune reconstitution while preventing GVHD, although this remains to be tested in a prospective trial and might have risks of sinusoidal obstruction syndrome when used with busulfan-based conditioning. 27 Conversely, the low incidence of aGVHD observed in patients without TME provides a rationale for a possible de-escalation of GVHD prophylaxis in certain select FIG 2. Probability of overall survival in patients with (solid line) and without (dashed line) TME. Overall survival was defined as survival after transplantation. There was no statistically significant difference in overall survival between these patient groups.
FIG 3.
Probability of event-free survival in patients with (solid line) and without (dashed line) TME. Event-free survival was defined as survival after transplantation without the need for additional (conditioned) transplant. There was no statistically significant difference in event-free survival between these patient groups.
scenarios, which would potentially allow for earlier immune reconstitution.
In conclusion, because the presence of pretransplantation TME is associated with an increased risk of GVHD, further consideration regarding GVHD prophylaxis should be given to these patients; the addition of serotherapy or other immunosuppressive agents might be warranted in these cases. The converse could also be true for TME 1 patients; for those with active infections, a de-escalation of GVHD prophylaxis might allow for earlier immune reconstitution and a reduction in infectionrelated morbidity and mortality.
One limitation of this analysis is that the underlying mechanisms that might contribute to the increased risk of aGVHD in TME 1 patients cannot be inferred from the available data. In addition, the study is retrospective, and there are multiple potential confounding variables. The small number of patients in this cohort restricted the opportunity for a more robust multivariate analysis. For example, the influence of TME status on the risk for aGVHD in recipients of nonmaternal grafts is not clear. Future analysis of patients with SCID enrolled on the prospective PIDTC registry study might allow for further examination of other potential variables that could influence development of posttransplantation aGVHD in these patients. Further studies are needed to better define the clinical risk factors and biologic mechanisms that mediate the effects of TME on the development of posttransplantation aGVHD.
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Clinical implications: This analysis provides additional data for assessing the risk for GVHD in a high-risk population. The presence of TME will inform timely diagnosis of GVHD, as well as prophylactic strategies. *cGVHD outcome was restricted to evaluable patients surviving more than 100 days after HSCT.
